Bank of America
CCCC icon

Bank of America’s C4 Therapeutics CCCC Stock Holding History

Bank of America’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.4M Buy
2,656,359
+297,118
+13% +$1.02M ﹤0.01% 2883
2026
Q1 		$6.2M Sell
2,359,241
-28,345
-1% -$66.7K ﹤0.01% 3303
2025
Q4 		$4.56M Buy
2,387,586
+334,424
+16% +$792K ﹤0.01% 3469
2025
Q3 		$4.56M Buy
2,053,162
+45,158
+2% +$108K ﹤0.01% 4105
2025
Q2 		$2.87M Buy
2,008,004
+17,180
+0.9% +$25K ﹤0.01% 4428
2025
Q1 		$3.19M Buy
1,990,824
+313,182
+19% +$934K ﹤0.01% 4256
2024
Q4 		$6.04M Sell
1,677,642
-358,591
-18% -$1.78M ﹤0.01% 3406
2024
Q3 		$11.6M Buy
2,036,233
+267,734
+15% +$1.61M ﹤0.01% 2929
2024
Q2 		$8.17M Sell
1,768,499
-86,659
-5% -$517K ﹤0.01% 3156
2024
Q1 		$15.2M Buy
1,855,158
+180,061
+11% +$1.4M ﹤0.01% 2555
2023
Q4 		$9.46M Buy
1,675,097
+1,629,756
+3,594% +$3.72M ﹤0.01% 2949
2023
Q3 		$84.3K Buy
45,341
+11,672
+35% +$35.6K ﹤0.01% 6316
2023
Q2 		$92.6K Sell
33,669
-17,819
-35% -$57.3K ﹤0.01% 6237
2023
Q1 		$162K Sell
51,488
-143,668
-74% -$846K ﹤0.01% 6030
2022
Q4 		$1.15M Buy
195,156
+55,969
+40% +$464K ﹤0.01% 4732
2022
Q3 		$1.22M Buy
139,187
+77,676
+126% +$806K ﹤0.01% 4724
2022
Q2 		$464K Sell
61,511
-42,267
-41% -$372K ﹤0.01% 5480
2022
Q1 		$2.52M Buy
103,778
+2,105
+2% +$51.1K ﹤0.01% 4366
2021
Q4 		$3.27M Buy
101,673
+80,122
+372% +$3.17M ﹤0.01% 4069
2021
Q3 		$963K Sell
21,551
-12,754
-37% -$546K ﹤0.01% 5124
2021
Q2 		$1.3M Sell
34,305
-14,469
-30% -$518K ﹤0.01% 4673
2021
Q1 		$1.8M Buy
48,774
+42,644
+696% +$1.7M ﹤0.01% 4354
2020
Q4 		$203K Buy
+6,130
New +$178K ﹤0.01% 5592

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America's CCCC Position: Q2 2026 in Review

Bank of America increased its C4 Therapeutics (CCCC) stake by 13% in Q2 2026, buying an estimated $1.02M and bringing the position to 2,656,359 shares worth $12.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2883.

Bank of America first reported a position in CCCC in Q4 2020 and has held it in 23 quarters since. The position peaked at $15.2M in Q1 2024. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Bank of America held 2,656,359 shares of C4 Therapeutics worth $12.4M as of Q2 2026.
  • Bank of America bought 297,118 C4 Therapeutics shares in Q2 2026, an estimated $1.02M.
  • C4 Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #2883 holding.
  • Bank of America first reported a position in C4 Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Bank of America's C4 Therapeutics position peaked at $15.2M in Q1 2024.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.